Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Sydney
About this trial
This trial will investigate the feasibility of the Markerless Tumour Tracking technology.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Is willing to comply with all trial procedures and intends to provide written Informed Consent for participation in this trial.
Patients undergoing external beam radiotherapy.
Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less).
MRI/4D-CT prior to insertion of fiducial markers.
Disqualifiers
Patient has low respiratory performance as evaluated by the physicians.
Previous high-dose thoracic radiotherapy.
Less than one fiducial marker implanted in the lung.
Fiducial markers are too far from the tumour centroid (>9 cm).
Trial design
Design model
Single group
Treatments tested in this trial
Markerless Image Guidance
DeviceSingle arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: Markerless Image Guidance ArmExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Markerless Tumour Tracking is feasible for motion-adaptive lung cancer radiotherapy
This will be measured by 90% of the treatment fractions achieving: 1. Continuous on-line tracking with no software failure; 2. Agreement between markerless and marker-based tracking within 3 mm in each direction (left-right, superior-inferior, anterior-posterior) for at least 80% of the beam-on time as assessed in off-line analyses.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov